Serlift, 50 mg 28 pcs

Serlift is an antidepressant derivative of naphthylamine. It is a selective blocker of serotonin neuronal reuptake in the brain.

The neuronal takeover of norepinephrine and dopamine is practically unaffected.

Serlift has no specific affinity for adreno- and m-cholinoreceptors, GABA receptors, dopamine, histamine, serotonin or benzodiazepine receptors. It does not inhibit MAOIs.

Causes anorexia and is effective in obsessive compulsive states.

Indications

Treatment of depressive states of various genesis in patients with mono- and bipolar affective disorders. Prevention of relapse episodes of depression.

Active ingredient

Composition

1 tablet contains sertraline 50 mg

How to take, the dosage

Sirlift is taken orally – 50 mg once a day, if necessary, the dose can be increased to 200 mg/day over several weeks.

The effect is seen 7 days after the start of treatment, reaching a maximum after 2-3 weeks.

Interaction

The prothrombin time is significantly increased with concomitant use of coumarin derivatives with santicoagulants.

Concomitant use of Sertraline may displace other drugs from binding to plasma proteins, resulting in increased plasma concentrations of the corresponding active substance and an increased risk of side effects.

Concomitant use with drugs metabolized with the help of CYP2D6 isoenzyme may increase plasma concentrations of these drugs due to inhibition of CYP2D6 isoenzyme by sertraline.

Concomitant use of MAO inhibitors (including selegiline and moclobemide) may cause serotonin syndrome (hyperthermia, muscle rigidity, myoclonus, and manifestations of mental and physiological instability, up to and including delirium and coma).

Concomitant use with lithium salts may increase tremor. Concomitant use with desipramine may increase the plasma concentration of desipramine; with cimetidine – a significant decrease in clearance of sertraline.

Special Instructions

With caution, use with a history of drug abuse or dependence, liver dysfunction, renal dysfunction, epileptic seizures, weight loss.

Do not use in patients undergoing electroconvulsive therapy. Sertraline may not be used earlier than 14 days after withdrawal of MAO inhibitors.

Do not drink alcohol during treatment.

The safety of use in pediatrics has not been established.

Impact on ability to drive and operate machinery

Activities requiring increased attention and high-speed psychomotor reactions should be avoided during treatment.

Contraindications

Simultaneous use with MAO inhibitors, hypersensitivity to sertraline.

Side effects

CNS disorders: dizziness, drowsiness, headache, insomnia, fatigue, weakness, tremor; rarely – manic or hypomanic state, anxiety, restlessness, visual disturbances.

Cardiovascular system disorders: rarely – redness of the skin with a feeling of heat or warmth, palpitations.

Digestive system disorders: decreased appetite, diarrhea, dry mouth, nausea, stomach or intestinal cramps, flatulence; rarely – constipation, vomiting.

Metabolic disorders: increased sweating.

Reproductive system: rarely – decreased potency.

Allergic reactions: rare – fever, skin rash, urticaria or itching.

Pregnancy use

Inadequate and well-controlled studies of the safety of sertraline in pregnancy have not been conducted, so use is possible only when the expected benefit to the mother outweighs the possible risk to the fetus.

It is not known whether sertraline is excreted with breast milk, so it is not recommended for use during lactation. Separate studies have shown that in infants whose mothers received sertraline while breastfeeding, its plasma levels are negligible or undetectable, while concentrations in breast milk exceed those in the mother’s blood.

Women of childbearing age should use reliable contraception during treatment with sertraline.

There have been no teratogenic and mutagenic effects of sertraline in experimental studies. However, at doses approximately 2.5-10 times the maximum daily clinical doses, sertraline caused delayed fetal bone ossification, possibly as a result of maternal effects. When sertraline was administered at doses approximately 5 times the maximum clinical doses, a decrease in neonatal survival was observed.

Similarities